|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Cost of revenues | |||||
| Energy storage system impairment | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| General and administrative expenses | |||||
| Research and development expenses | |||||
| Selling and marketing expenses | |||||
| Impairment loss of long-lived assets | |||||
| Total operating expenses | |||||
| Subsidy income | |||||
| Income/(loss) from operations | |||||
| Other income and expenses: | |||||
| Interest income | |||||
| Loss on changes in fair value of Bridge Notes | |||||
| Interest expense | |||||
| Changes in fair value of warrant liability and convertible loan | |||||
| Gain on debt restructuring | |||||
| Other income (expense), net | |||||
| Loss before provision for income tax | |||||
| Benefit from (provision for) income taxes | |||||
| Net loss | |||||
| Net loss attributable to noncontrolling interests | |||||
| Net loss attributable to common stockholders | |||||
| Less: Accretion of Series C1 Preferred | |||||
| Less: Accretion of Series C2 Preferred | |||||
| Less: Accretion of Series D1 Preferred | |||||
| Less: Accretion for noncontrolling interests | |||||
| Net loss attributable to common stock shareholders of Microvast Holdings, Inc. | |||||
| Earnings Per Share | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Weighted Average Number of Shares Outstanding | |||||
| Weighted average shares used in calculating net loss per share of common stock, basic (in shares) | |||||
| Weighted average shares used in calculating net loss per share of common stock, diluted (in shares) | |||||
Loading...